PO107

Brachytherapy Pub Date : 2023-09-01 DOI:10.1016/j.brachy.2023.06.208

Zhe Ji, Yang Ni, Chuang He, Xuequan Huang, Xin Ye, Junjie Wang

{"title":"PO107","authors":"Zhe Ji, Yang Ni, Chuang He, Xuequan Huang, Xin Ye, Junjie Wang","doi":"10.1016/j.brachy.2023.06.208","DOIUrl":null,"url":null,"abstract":"Purpose To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. Materials and Methods The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. Results The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group was better than that in the MWAT group. The 1-year, 3-year and 5-year PFS of RSABT and MWAT group were 87.3%, 72.6%, 65.8% and 89.5%, 69.3% and 43.7% respectively (P = 0.011); the overall survival (OS) of RSABT group was slightly better than MWAT group. The 1-year, 3-year and 5-year OS of the two groups were 97.2%, 78.1%, 66.1% and 99%, 75.8% and 55% respectively (P = 0.112). Treatment technology was also an independent factor affecting PFS (HR 0.48, 95%CI 0.28-0.83, P=0.008) in multivariate Cox analysis. And gender and T stage were independent factors affecting PFS and OS (P < 0.05). There are no fatal operation related complications. Pneumothorax was the most common complication. The incidence of MWAT group was slightly higher than that of RSABT group, which were 50% and 39% respectively (P = 0.313). The incidence of pleural effusion in MWAT group was higher than that in RSABT group (44% and 14%, respectively, P < 0.001). The incidence of needle bleeding in RSABT group was higher than that in MWAT group (32% and 5%, respectively, P < 0.001). Conclusions The outcomes of RSABT in the treatment of early NSCLC is no less than MWAT, and the incidence of operation complications is also equivalent to MWAT, but further exploration is needed. To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group was better than that in the MWAT group. The 1-year, 3-year and 5-year PFS of RSABT and MWAT group were 87.3%, 72.6%, 65.8% and 89.5%, 69.3% and 43.7% respectively (P = 0.011); the overall survival (OS) of RSABT group was slightly better than MWAT group. The 1-year, 3-year and 5-year OS of the two groups were 97.2%, 78.1%, 66.1% and 99%, 75.8% and 55% respectively (P = 0.112). Treatment technology was also an independent factor affecting PFS (HR 0.48, 95%CI 0.28-0.83, P=0.008) in multivariate Cox analysis. And gender and T stage were independent factors affecting PFS and OS (P < 0.05). There are no fatal operation related complications. Pneumothorax was the most common complication. The incidence of MWAT group was slightly higher than that of RSABT group, which were 50% and 39% respectively (P = 0.313). The incidence of pleural effusion in MWAT group was higher than that in RSABT group (44% and 14%, respectively, P < 0.001). The incidence of needle bleeding in RSABT group was higher than that in MWAT group (32% and 5%, respectively, P < 0.001). The outcomes of RSABT in the treatment of early NSCLC is no less than MWAT, and the incidence of operation complications is also equivalent to MWAT, but further exploration is needed.","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"74 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brachytherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.brachy.2023.06.208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. Materials and Methods The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. Results The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group was better than that in the MWAT group. The 1-year, 3-year and 5-year PFS of RSABT and MWAT group were 87.3%, 72.6%, 65.8% and 89.5%, 69.3% and 43.7% respectively (P = 0.011); the overall survival (OS) of RSABT group was slightly better than MWAT group. The 1-year, 3-year and 5-year OS of the two groups were 97.2%, 78.1%, 66.1% and 99%, 75.8% and 55% respectively (P = 0.112). Treatment technology was also an independent factor affecting PFS (HR 0.48, 95%CI 0.28-0.83, P=0.008) in multivariate Cox analysis. And gender and T stage were independent factors affecting PFS and OS (P < 0.05). There are no fatal operation related complications. Pneumothorax was the most common complication. The incidence of MWAT group was slightly higher than that of RSABT group, which were 50% and 39% respectively (P = 0.313). The incidence of pleural effusion in MWAT group was higher than that in RSABT group (44% and 14%, respectively, P < 0.001). The incidence of needle bleeding in RSABT group was higher than that in MWAT group (32% and 5%, respectively, P < 0.001). Conclusions The outcomes of RSABT in the treatment of early NSCLC is no less than MWAT, and the incidence of operation complications is also equivalent to MWAT, but further exploration is needed. To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group was better than that in the MWAT group. The 1-year, 3-year and 5-year PFS of RSABT and MWAT group were 87.3%, 72.6%, 65.8% and 89.5%, 69.3% and 43.7% respectively (P = 0.011); the overall survival (OS) of RSABT group was slightly better than MWAT group. The 1-year, 3-year and 5-year OS of the two groups were 97.2%, 78.1%, 66.1% and 99%, 75.8% and 55% respectively (P = 0.112). Treatment technology was also an independent factor affecting PFS (HR 0.48, 95%CI 0.28-0.83, P=0.008) in multivariate Cox analysis. And gender and T stage were independent factors affecting PFS and OS (P < 0.05). There are no fatal operation related complications. Pneumothorax was the most common complication. The incidence of MWAT group was slightly higher than that of RSABT group, which were 50% and 39% respectively (P = 0.313). The incidence of pleural effusion in MWAT group was higher than that in RSABT group (44% and 14%, respectively, P < 0.001). The incidence of needle bleeding in RSABT group was higher than that in MWAT group (32% and 5%, respectively, P < 0.001). The outcomes of RSABT in the treatment of early NSCLC is no less than MWAT, and the incidence of operation complications is also equivalent to MWAT, but further exploration is needed.

查看原文本刊更多论文

PO107

目的比较放射性I-125粒子近距离消融术(RSABT)与微波消融术(MWAT)治疗不能手术的早期非小细胞肺癌的疗效和安全性。材料与方法纳入我们合作组2010年12月至2020年11月接受CT引导下RSABT和MWAT治疗的早期非小细胞肺癌患者的资料。主要结局指标为无进展生存期，次要结局指标为总生存率和不良事件。Kaplan-Meier法分析无进展生存期和总生存期。分别采用Logistic回归和Cox回归进行单因素和多因素分析。结果RSABT组和MWAT组患者的中位随访时间分别为47.4个月和60个月。RSABT组无进展生存期(PFS)优于MWAT组。RSABT组和MWAT组1年、3年、5年PFS分别为87.3%、72.6%、65.8%、89.5%、69.3%、43.7% (P = 0.011);RSABT组总生存率(OS)略优于MWAT组。两组患者1年、3年、5年OS分别为97.2%、78.1%、66.1%、99%、75.8%、55% (P = 0.112)。多因素Cox分析显示，治疗技术也是影响PFS的独立因素(HR 0.48, 95%CI 0.28-0.83, P=0.008)。性别和T分期是影响PFS和OS的独立因素(P < 0.05)。没有致命的手术并发症。气胸是最常见的并发症。MWAT组的发病率略高于RSABT组，分别为50%和39% (P = 0.313)。MWAT组胸腔积液发生率高于RSABT组(分别为44%和14%，P < 0.001)。RSABT组针头出血发生率高于MWAT组(分别为32%和5%，P < 0.001)。结论RSABT治疗早期NSCLC的疗效不低于MWAT，手术并发症发生率也与MWAT相当，但仍需进一步探索。比较放射性I-125粒子近距离消融术(RSABT)与微波消融术(MWAT)治疗不能手术的早期非小细胞肺癌的疗效和安全性。纳入我们合作组2010年12月至2020年11月接受CT引导下RSABT和MWAT治疗的早期非小细胞肺癌患者的数据。主要结局指标为无进展生存期，次要结局指标为总生存率和不良事件。Kaplan-Meier法分析无进展生存期和总生存期。分别采用Logistic回归和Cox回归进行单因素和多因素分析。RSABT组和MWAT组患者的中位随访时间分别为47.4个月和60个月。RSABT组无进展生存期(PFS)优于MWAT组。RSABT组和MWAT组1年、3年、5年PFS分别为87.3%、72.6%、65.8%、89.5%、69.3%、43.7% (P = 0.011);RSABT组总生存率(OS)略优于MWAT组。两组患者1年、3年、5年OS分别为97.2%、78.1%、66.1%、99%、75.8%、55% (P = 0.112)。多因素Cox分析显示，治疗技术也是影响PFS的独立因素(HR 0.48, 95%CI 0.28-0.83, P=0.008)。性别和T分期是影响PFS和OS的独立因素(P < 0.05)。没有致命的手术并发症。气胸是最常见的并发症。MWAT组的发病率略高于RSABT组，分别为50%和39% (P = 0.313)。MWAT组胸腔积液发生率高于RSABT组(分别为44%和14%，P < 0.001)。RSABT组针头出血发生率高于MWAT组(分别为32%和5%，P < 0.001)。RSABT治疗早期NSCLC的效果不低于MWAT，手术并发症发生率也与MWAT相当，但还需进一步探索。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brachytherapy

自引率

0.00%

发文量